Renata Faermann, Eitan Friedman, Orit Kaidar-Person, Jonathan Weidenfeld, Malka Brodsky, Anat Shalmon, Osnat Halshtok Neiman, Michael Gotlieb, Yael Yagil, David Samoocha, Dana Madorsky Feldman, Miri Sklair-Levy
{"title":"Ductal Carcinoma In Situ (DCIS) Diagnosed by MRI-Guided Biopsy among <i>BRCA1/BRCA2</i> Mutation Carriers.","authors":"Renata Faermann, Eitan Friedman, Orit Kaidar-Person, Jonathan Weidenfeld, Malka Brodsky, Anat Shalmon, Osnat Halshtok Neiman, Michael Gotlieb, Yael Yagil, David Samoocha, Dana Madorsky Feldman, Miri Sklair-Levy","doi":"10.1155/2022/4317693","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>While <i>BRCA1/BRCA2</i> pathogenic sequence variants (PSVs) clearly confer an increased risk for invasive breast cancer, the extent to which these mutant alleles increase DCIS risk is less clear.</p><p><strong>Objective: </strong>To assess the rate of detection over a 5-year period, and MRI imaging features of pure noncalcified DCIS in a cohort of Israeli <i>BRCA1/BRCA2</i> PSV carriers attending a high-risk clinic from 2015 to 2020.</p><p><strong>Materials and methods: </strong>All female <i>BRCA1/BRCA2</i> PSV-carriers followed at the Meirav High-risk clinic from 2015 to 2020 were eligible if they underwent semiannual breast imaging (MRI/mammography) and MRI-guided biopsy-proven pure DCIS. Clinical data, pathology information, and imaging characteristics were retrieved from the computerized archiving system.</p><p><strong>Results: </strong>18/121 (15.2%) participating <i>BRCA1</i> PSV carriers and 8/81 (10.1%) <i>BRCA2</i> PSV-carriers who underwent MRI-guided biopsy were diagnosed with DCIS. The median age of <i>BRCA1</i> carriers and <i>BRCA2</i> carriers was 49.8 years and 60.6 years, respectively (<i>p</i> = 0.55). Negative estrogen-receptor tumors were diagnosed in 13/18 (72%) <i>BRCA1</i> and 2/8 (25%) <i>BRCA2</i> PSV carriers (<i>p</i> < 0.05). Thirteen (13/18-72%) <i>BRCA1</i> carriers had intermediate to high-grade or high-grade DCIS compared with 4/8 (50%) of <i>BRCA2</i> carriers (<i>p</i> = 0.03). Over the 5-year study period, 29/1100 (2.6%) <i>BRCA1/BRCA2</i> PSV carriers were diagnosed with DCIS seen on MRI only.</p><p><strong>Conclusion: </strong>MRI-detected noncalcified DCIS is more frequent in <i>BRCA1</i> PSV carriers compared with <i>BRCA2</i> carriers, unlike the <i>BRCA2</i> predominance in mammography-detected calcified DCIS. <i>BRCA1</i>-related DCIS is diagnosed earlier, more likely to be estrogen receptor-negative and of higher grade compared with <i>BRCA2</i>-related DCIS. Future prospective studies should validate these results and assess the actual impact they might have on clinical management of <i>BRCA</i> PSV carriers.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2022 ","pages":"4317693"},"PeriodicalIF":1.9000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633198/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2022/4317693","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 2
Abstract
Background: While BRCA1/BRCA2 pathogenic sequence variants (PSVs) clearly confer an increased risk for invasive breast cancer, the extent to which these mutant alleles increase DCIS risk is less clear.
Objective: To assess the rate of detection over a 5-year period, and MRI imaging features of pure noncalcified DCIS in a cohort of Israeli BRCA1/BRCA2 PSV carriers attending a high-risk clinic from 2015 to 2020.
Materials and methods: All female BRCA1/BRCA2 PSV-carriers followed at the Meirav High-risk clinic from 2015 to 2020 were eligible if they underwent semiannual breast imaging (MRI/mammography) and MRI-guided biopsy-proven pure DCIS. Clinical data, pathology information, and imaging characteristics were retrieved from the computerized archiving system.
Results: 18/121 (15.2%) participating BRCA1 PSV carriers and 8/81 (10.1%) BRCA2 PSV-carriers who underwent MRI-guided biopsy were diagnosed with DCIS. The median age of BRCA1 carriers and BRCA2 carriers was 49.8 years and 60.6 years, respectively (p = 0.55). Negative estrogen-receptor tumors were diagnosed in 13/18 (72%) BRCA1 and 2/8 (25%) BRCA2 PSV carriers (p < 0.05). Thirteen (13/18-72%) BRCA1 carriers had intermediate to high-grade or high-grade DCIS compared with 4/8 (50%) of BRCA2 carriers (p = 0.03). Over the 5-year study period, 29/1100 (2.6%) BRCA1/BRCA2 PSV carriers were diagnosed with DCIS seen on MRI only.
Conclusion: MRI-detected noncalcified DCIS is more frequent in BRCA1 PSV carriers compared with BRCA2 carriers, unlike the BRCA2 predominance in mammography-detected calcified DCIS. BRCA1-related DCIS is diagnosed earlier, more likely to be estrogen receptor-negative and of higher grade compared with BRCA2-related DCIS. Future prospective studies should validate these results and assess the actual impact they might have on clinical management of BRCA PSV carriers.
期刊介绍:
The Breast Journal is the first comprehensive, multidisciplinary source devoted exclusively to all facets of research, diagnosis, and treatment of breast disease. The Breast Journal encompasses the latest news and technologies from the many medical specialties concerned with breast disease care in order to address the disease within the context of an integrated breast health care. This editorial philosophy recognizes the special social, sexual, and psychological considerations that distinguish cancer, and breast cancer in particular, from other serious diseases. Topics specifically within the scope of The Breast Journal include:
Risk Factors
Prevention
Early Detection
Diagnosis and Therapy
Psychological Issues
Quality of Life
Biology of Breast Cancer.